SERÁN BIOSCIENCE EXPANDS TO COMMERCIAL MANUFACTURING WITH NEW 100,000 SQ. FT. FACILITY IN BEND, OREGON

SERÁN BIOSCIENCE EXPANDS TO COMMERCIAL MANUFACTURING WITH NEW 100,000 SQ. FT. FACILITY IN BEND, OREGON

Bend, OR — August 14, 2025 — Serán BioScience, LLC, a leading science-driven drug development partner, today announced the groundbreaking of its new 100,000 ft2 commercial manufacturing facility in Bend, Oregon. This expansion marks a significant milestone in Serán’s mission to provide fully integrated support from first-in-human (FiH) trials through commercial-scale production of small-molecule therapeutics. Enabled by an investment from Bain Capital Life Sciences in September, 2024, the new greenfield site enhances Serán’s ability to serve pharmaceutical innovators with a true end-to-end partner for complex oral solid dosage forms. Specializing in spray drying, particle engineering, and advanced drug formulation, the US facility is purpose-built to produce commercial-scale, non-sterile solid dose products with high scientific rigor and world-wide regulatory compliance.

“Our investment in commercial manufacturing capabilities is a direct response to the evolving needs of our clients,” said Dan Smithey, CEO of Serán BioScience. “Pharmaceutical companies are increasingly looking for integrated partners who can not only optimize performance at the clinical stage but also deliver scalable solutions that accelerate time-to-market. This facility delivers on that promise.”

Adjacent to the new plant, Serán has also completed two newly constructed warehouse and light manufacturing buildings totaling 50,000 ft2. These facilities support advanced materials management, packaging, labeling, and other critical logistics functions essential for seamless scale-up and supply chain reliability.

Strategically located just minutes from Serán’s existing 90,000 ft2 clinical development and manufacturing campus, the new commercial site will integrate with the company’s established clinical operations. The Bend campus houses over 190 highly skilled professionals and features 10 specialized buildings equipped with cutting-edge technologies including nano milling, micronization, dry and wet granulation, spray-dried dispersions, twin-screw melt extrusion, and more. These capabilities span the full spectrum of oral solid dose development, from early-phase formulation through clinical trial manufacturing, packaging, and labeling.

Serán’s expansion reflects its deep commitment to supporting both emerging biotech firms and large pharmaceutical organizations with flexible, science-forward solutions that translate innovation into commercially viable therapies. For pharmaceutical leaders seeking a strategic manufacturing partner with deep scientific capabilities and an unwavering focus on quality and scalability, Serán BioScience now offers a comprehensive path from molecule to market.

‍

[ends]

‍

For Inquiries:

‍

Brinette Holdren

Director of Marketing

Serán BioScience

Holdren@seranbio.com

‍